Skin Diseases  >>  Halaven (eribulin mesylate)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
NCT01142661: Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Completed
N/A
9
US
Eribulin Mesylate
Eisai Inc.
Breast Cancer
08/11
 
NCT01463891: Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Completed
N/A
963
Japan
Eribulin Mesylate
Eisai Co., Ltd.
Inoperable or Recurrent Breast Cancer
12/12
11/13
NCT01240421 / 2009-017671-22: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Approved for marketing
N/A
Canada, Europe
Eribulin Mesylate
Eisai Inc.
Metastatic Breast Cancer
03/15
11/14

Download Options